Literature DB >> 12210731

Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.

Lorenz C Hofbauer1, Sibylle Kluger, Christian A Kühne, Colin R Dunstan, Andreas Burchert, Michael Schoppet, Andreas Zielke, Armin E Heufelder.   

Abstract

Receptor activator of NF-kappaB (RANK) ligand (RANKL) and osteoprotegerin (OPG) play essential roles in bone metabolism and immune responses. RANKL activates RANK, which is expressed by osteoclasts and dendritic cells (DC), whereas OPG acts as its decoy receptor. The role of RANKL and OPG in thyroid physiology is unclear. Northern analysis revealed pronounced OPG mRNA levels in normal human thyroid. By contrast, RANKL mRNA levels were most abundant in lymph node and appendix, and low in the thyroid. In the human thyroid follicular cell line XTC and in primary human thyroid follicular cells, OPG mRNA levels and protein secretion were upregulated by interleukin (IL)-1beta (33-fold), tumor necrosis factor (TNF)-alpha (eightfold), and thyrotropin (TSH) (threefold). RANKL mRNA was stimulated in XTC by IL-1beta and TNF-alpha, but inhibited by TSH. Conditioned medium harvested from IL-1beta-treated XTC (containing high concentrations of OPG) inhibited RANKL-induced CD40 upregulation and cluster formation of DC. OPG mRNA levels were three times more abundant in surgical thyroid specimens of Graves' disease as compared to other thyroid diseases. Our data suggest that RANKL and OPG are produced in the thyroid gland by thyroid follicular cells, are regulated by cytokines and TSH, and are capable of modulating dendritic cell functions. Thus, these cytokines may represent important local immunoregulatory factors involved in the pathogenesis of autoimmune thyroid diseases. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210731     DOI: 10.1002/jcb.10242

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.

Authors:  Risheng Ma; Syed Morshed; Rauf Latif; Mone Zaidi; Terry F Davies
Journal:  Thyroid       Date:  2011-07-11       Impact factor: 6.568

2.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

3.  Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients.

Authors:  X Guang-Da; S Hui-Ling; C Zhi-Song; Z Lin-Shuang
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

4.  Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death.

Authors:  J Schrader; W Rennekamp; U Niebergall; M Schoppet; H Jahr; M D Brendel; D Hörsch; L C Hofbauer
Journal:  Diabetologia       Date:  2007-04-19       Impact factor: 10.122

5.  Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer.

Authors:  Youjin Lee; Byung-Ho Yoon; Seeyoun Lee; Youn Kyung Chung; Young-Kyun Lee
Journal:  J Bone Metab       Date:  2019-02-28

6.  Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  BMC Cancer       Date:  2015-11-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.